Protabit engineers proteins for industrial, agricultural, and healthcare applications. Its platform technology is being developed via a strategic partnership with the Monsanto Company and the California Institute of Technology. Protabit’s protein engineering approach combines computational modeling with high-throughput screening and directed evolution to expand the diversity of protein sequences that can be explored to produce novel proteins.
BioSuperior is a preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue. They have bio-engineered a novel synthetic pulmonary surfactant prototype, BioSurf, an essential biomaterial required for breathing and having direct therapeutic effects that will be used to deliver potent drugs that restore normal lung function.
Aqua Science offers a global platform of technologies and fast and reliable solutions for the testing and treatment of water. They provide research and development, custom reagent and kit manufacture, product assembly, lyophilization services, and contract manufacturing services.
Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence. Their first target disease is citrus greening, an incurable and debilitating disease that costs the United States more than $2 billion each year. Uniphage created the first commercially effective models for computationally predicting safe bacterial viruses against target bacterial infections, as well as discovered a variety of targets. This enables them to deliver new antimicrobial, safe, and precise products to market much more quickly.
Canomiks provides a genomics, bioinformatics and AI-based Product Superiority Platform that enables companies within the functional food and beverage, dietary supplement and skincare industries to create safe and efficacious products. Canomiks' long-term vision is to make food as medicine a reality.
Auctus Biologics is a pre-clinical biotechnology company focused on developing antibody mimetics for therapeutic and diagnostic uses. By engineering a ribose-binding protein, the company aims to create a scaffold that binds clinical targets with an affinity comparable to monoclonal antibodies while addressing the limitations associated with traditional antibodies. These limitations include instability and the need for costly cold-chain logistics, which can hinder their effectiveness in extreme environments such as the gastrointestinal tract. Auctus Biologics' innovative approach allows for treatments that are not only more resilient, capable of withstanding conditions like repeated boiling cycles, but also more accessible and cost-effective for patients. This advancement may significantly enhance the delivery of advanced medical therapies.
MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.
OPOS operates a patient monitoring and opioid prescriber compliance platform designed to assist primary care and pain specialists across various practice settings. The company focuses on ensuring that opioid prescribers adhere to guidelines set by the Centers for Disease Control and Prevention, state authorities, and medical boards. By providing documented evidence of compliance, along with clinical decision support, OPOS enables healthcare providers to enhance patient outcomes and assess individual and collective risks associated with patients, prescribers, and practices. Their services not only promote regulatory compliance but also aim to reduce prescribing risks and administrative overhead, thus generating revenue through improved operational efficiency in opioid treatment.
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.
BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.
Medecipher is a highly innovative early stage company providing innovative solutions to help hospitals improve their operations.
Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.
Fortiphyte offers agricultural protection products that help to protect crops from disease and reduce fungicide use. The company was founded in 2017 and is based in Berkeley, California.
Developer of gastrointestinal therapeutic device designed for the alleviation of postoperative ileus and the restoration of gastrointestinal motility. The company's device aims to revolutionize medical science by using bioelectronic medicine for the treatment of diseases and injuries incurable pharmaceutically and is capable of developing miniaturized implantable device, while retaining sophisticated functionality with various electrode shape and number, enabling clinicians to treat diseases and injuries through neuromodulation.
Pyran LLC specializes in developing a starting compound for the production of paints and plastic chemicals. Founded in 2017 and based in Madison, Wisconsin, the company creates a diol product derived from renewable wood and crop waste resources. This diol serves as a raw material for various applications, including digital versatile discs, paints, bottles, coatings, plastics, ropes, glues, and adhesives. Pyran primarily caters to the chemical industries, focusing on sustainable solutions for paint and plastic manufacturing.
Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.
Developer of industrial enzymes intended to provide high value enzymes and chemical entities to businesses. The company develops combination of disparate disciplines to overcome problems that are not amenable to throughput screening methodologies in order to discover new, high value enzymes and chemical entities, enabling organizations to produce and market chemical products and processes through contract or in partnership .
TheraCea Pharma is a biotechnology company that develops precision medicine to help people with neurological disorders. TheraCea Pharma, a University of Arizona spin-off based in Tucson, developed and licensed radiochemistry technology that allows for high-efficiency and rapid fluorine-18 radiolabeling of biomolecules for clinical and research applications.
Developer of neurodiagnostic technologies intended to commercialize blood testing products. The company provides critical data that can be useful in diagnosis, monitoring and assessing therapeutic responses that help to make discoveries for brain health and diseases, enabling pharmaceutical companies and researchers to drug discovery and conduct studies in brain disease.
Nano PharmaSolutions improves the bioavailability of insoluble drugs using innovative, revolutionary nanoformulation. Nano PharmaSolutions offers a phase-transition technology platform that can reliably enhance the solubility of BCS 2 and BCS 4 APIs without the use of excipients (e.g. large volumes of volatile solvents) used in such processes as spray dry dispersion, hot-melt extrusion, and emulsification. Their patented technology platform deposits vaporized API onto the surface of a carrier molecule which is further processable into the full spectrum of existing dosage forms.
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focus on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.
Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.
MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.
Paramita Therapeutics is a San Diego-based biotech company established in 2018 that specializes in developing innovative therapeutics for cancer and infectious diseases. The company employs a patented multi-functional chemical platform to facilitate the rapid transition of new therapies from the laboratory to clinical settings. By focusing on multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles, Paramita Therapeutics aims to enhance patient access to effective cancer treatments and dual-function therapeutic and vaccine products.
Developer of recombinant protein-based materials designed to mimic those naturally found in this environment. The company's products have core protein biometrics composed of a simple modular design, translated into a system that forms fractal-like porous networks with material properties after injection and exposure to body heat, enabling medical researchers to get the required bio-compatible materials used in tissue engineering and regenerative medicine.
Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.
Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.
SpheroFill is a drug delivery platform that specializes in the development of injectable tissue fillers, particularly for treating age-related atrophy in the larynx. The company utilizes a unique combination of solid, hollow, and porous-wall hollow glass microspheres mixed with biocompatible and bioactive matrices. This innovative approach enhances the delivery of active pharmaceutical ingredients (APIs) in various forms, including solids, liquids, and gases. By improving compliance through reduced dosing frequency and enabling previously impossible oral formulations, SpheroFill is positioned as a leader in advancing drug delivery technology, offering healthcare professionals enhanced devices for more effective treatments.
Wildlife Protection Management, Inc. manufactures a dart system for delivering vaccines and contraceptives on the horses. Its system also allows for the delivery of radio-frequency identification (RFID) chips for identifying each horse and monitoring the health and location. Wildlife Protection Management, Inc. was incorporated in 2018 and is based in Albuquerque, New Mexico.
Operator of an agricultural biotechnology company committed to developing and producing allergen-free peanuts. The company develops its agricultural products using technology like genomics, proteomics, plant tissue culture and plant propagation, providing consumers with high-value agricultural products that enhance and save human lives.
Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.
CellDrop Biosciences, established in 2017 and based in Laramie, Wyoming, specializes in hydrogel-based technology for point-of-care diagnostics and targeted biomaterial delivery. The company focuses on developing hydrogel platforms that enable precise control over chemical and biological systems. Its innovations aim to facilitate the healing of equine musculoskeletal injuries efficiently, while also minimizing the risk of re-injury. By providing effective diagnostic and treatment solutions, CellDrop Biosciences addresses critical needs within the veterinary medical community.
Enable Therapeutics
Grant in 2021
Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.
Developer of life science platform intended to provide accurate methods to test dangerous endotoxins. The company provides advanced healthcare innovations for the detection of blood-borne pathogens, enabling physicians to develop a rapid and sensitive diagnostic for detecting bloodstream infection.
Phosio serves the tech hardware industry with nano-imprintable high index optical materials for use in components such as Augmented Reality, OLED, micro-LED and more. Materials are only as good as they are manufacturable. We make transparent high refractive index, 1.6 < n < 2.4, solutions viable for mass production.
Impact Proteomics, LLC specializes in protein sample preparation, offering a range of kits and reagents designed to produce contaminant-free samples. Founded in 2017 and based in Pittsburgh, Pennsylvania, the company provides various products, including Universal Protein Extraction and Clean Kits for peptides, whole proteins, and immunoprecipitation, as well as Promtag Reversible Protein Tagging Agents and related accessories. By supplying tools for efficient protein handling, Impact Proteomics aims to enhance drug and biomarker discovery processes, allowing researchers to accelerate the development of therapeutics and diagnostics. The company's offerings are available for purchase online, reflecting its commitment to supporting the scientific community in advancing medical research.
New Horizon Biotech specializes in biotechnology and biopharmaceutical products, focusing on optimizing supply chains and ensuring consistent quality globally at a reduced cost. The company is finalizing tests of its patented Single Use Horizontal Fermentor system (SUHF™), which is designed for single-use microbial fermentation. This innovative system is set to enhance production efficiencies and operational cost savings, offering significant advantages over traditional fermentor designs. By improving the microbial fermentation process, New Horizon Biotech aims to support the production of high-value biopharmaceuticals, including antibiotics, vaccines, and therapeutic proteins, thereby strengthening the global competitive edge of its clients.
Sunthetics specializes in developing advanced electrochemical reactors that significantly enhance the efficiency of process chemists in the pharmaceutical industry. By utilizing smart electrochemical equipment and machine-learning software, Sunthetics enables the rapid development of lead molecules, reducing the typical process development time by 90%. This innovative approach not only cuts energy consumption by 40% but also eliminates the use of toxic chemicals and waste, promoting sustainability in chemical manufacturing. While the initial focus is on pharmaceuticals, the technology has the potential to expand into other sectors such as agrochemicals and specialty chemicals, positioning Sunthetics at the forefront of the electrification movement within the chemical industry.
VeriSIM Life, Inc. develops disease-specific biosimulation models that allow researchers at pharmaceutical companies to model in software how a drug will interact in animals. The company was incorporated in 2017 and is based in San Francisco, California.
FibrosIX is a biotechnology company develops drugs to prevent lung fibrosis in cancer patients. The company was founded in 2016 and is headquartered in East Lansing, Michigan.
Operator of a biotechnology company intended to improve research, health, and wellness by providing access to accurate and cost-effective specimen collection devices. The company's device stabilized sensitive tests and facilitates remote specimen collection, including urine, serum, plasma, or any other bodily fluid, and simple transportation at ambient temperature, enabling people in the community to access accurate and cost-effective diagnoses.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Souvie Biodelivery develops drug delivery services with the goal of marketing novel drug delivery platforms to drug delivery niche markets. The company was founded in 2018 and is headquartered in Tucson, Arizona.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Creative BioTherapeutics is a biotechnology company developing therapies for cancer and viruses. The company is changing the way that cancer and viral disease research is conducted. It focuses on the root cause of cancer affecting immune evasion and drug resistance.
Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts, founded in 2016. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves programming bacteria to deliver intracellular macromolecules directly into tumor tissues. These engineered bacteria are motile, allowing them to actively penetrate and target metastatic diseases and inoperable tumors. Through these advancements, Ernest Pharmaceuticals aims to enhance treatment options for patients facing challenging cancer diagnoses.
Developer of encapsulation technology-based drugs designed to use biologics, peptides, and RNA to treat disease. The company's technology addresses current issues with many biologics and peptide therapeutics, by protecting and delivering agents to their intended targets within the body, enabling patients with sustained delivery of peptide therapeutics using nano-composite microparticles.
Saphtx develops protein-based therapeutic strategies for a wide range of diseases. The company was founded in 2018 and is headquartered in Newark, New Jersey.
TEGA Therapeutics, Inc. is focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Founded in 2013 and based in La Jolla, California, the company specializes in enhancing the delivery of enzyme replacement therapies to the brain, particularly for lysosomal storage disorders. By leveraging glycoside-enhanced delivery methods, TEGA addresses significant challenges in reaching the central nervous system, thereby improving treatment outcomes. Additionally, the company produces bio-engineered heparan sulfate and heparin, which play crucial roles in various physiological processes. TEGA's mission is to improve the quality of life for patients by providing innovative solutions for unmet medical needs, utilizing rigorous scientific methods to advance the therapeutic potential of glycans in medicine.
Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.
Ionica Sciences™ is utilizing a new technology platform to meet urgent needs in clinical diagnostics.The ability to rapidly and accurately identify the presence of diseases would provide clinicians with the ability to reduce suffering of their patients, the use of antibiotics, and healthcare costs that result from mis- or missed diagnoses.
Bondwell Technologies is a biotechnology company focused on developing biomaterial-based technologies that leverage the natural properties of proteins and molecular tools. The company's innovative materials possess diverse structural, mechanical, and functional attributes tailored for various applications. These applications span multiple fields, including tissue engineering, biosensing, drug delivery, and photonics. By optimizing its technologies, Bondwell aims to facilitate advancements in energy, environmental science, and medicine, enabling researchers to make significant contributions across these critical areas.
FYR Diagnostics, founded in 2016 and based in Missoula, Montana, focuses on developing biomarker detection technology aimed at addressing chronic diseases in both human healthcare and agriculture. The company aims to tackle significant clinical challenges by commercializing innovative technologies that enhance the prediction, diagnosis, and management of diseases. This approach targets disorders that currently suffer from inadequate treatment and diagnostic options, thereby offering potential solutions for healthcare professionals and agricultural sectors facing substantial unmet needs.
Solving gout using engineered probiotics
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Thermaquil, Inc. develops and sells medical devices to control pain and other conditions caused by overactive nerves. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Travera, LLC operates in the biotechnology industry. The company uses Suspended Microchannel Resonator device to measure change in the weight of a single cancer cell called Mass Accumulation Rate (MAR) biomarker to determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Inherent Biosciences is a molecular diagnostics company that revolutionizes trial and error medicine and restore hope. The company does this by discovering what's inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Inherent Biosciences develops medicines for treating pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, COVID-19, and many more.
Developer of high-brightness fluorophores designed to improve the reagents that run through flow cytometers. The company's fluorophores are compatible with current flow cytometers and increase the brightness of fluorophores across the visible range with minimal or no noise distortion, enabling users to detect targeted or cancer cells feasibly.
General Probiotics (GP) is a biotechnology company that discovers, develops and commercializes a new class of antimicrobial medicines for infectious diseases. GP engineers are world leaders in advanced probiotics. GP probiotics are tailored to eliminate pathogens effectively and reliably. GP has been awarded Small Business Innovative Research grants by the US National Science Foundation and the US Department of Agriculture to pursue an unparalleled, AI-enabled R&D program.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.
Developer of a cloud-based SaaS platform designed to provide data relating to medical drug discovery. The company's software specializes in providing mass spectrometry data processing, analysis, reporting, and visualization for every instrument, molecule, algorithm, and workflow, allowing scientists to research and develop drugs and providing them with tools for spectrometry.
QATCH Technologies company that’s developing a tool to determine the injectability and manufacturability of biopharmaceutical products. Its proprietary technology can determine if a formulation is injectable or if there will be viscosity related manufacturing problems at very early stages.
Intact Therapeutics designs and develops a thermosensitive drug delivery platform for the treatment of gastrointestinal (GI) disorders. The company was founded in 2015 and is based in Belmont, California.
Curie Co. Inc. is a life science company based in New York that specializes in the production of engineered enzymes and biopolymers, primarily for the personal care, pharmaceutical, and healthcare industries. Founded in 2017, the company aims to replace harmful and banned chemicals with sustainable alternatives derived from recycled marine biomaterials, branded as OceanSafe. These innovative materials are designed to eliminate the need for preservatives and are utilized to create biodegradable bioplastics for various applications, including microbeads, packaging, and films. Curie Co. focuses on providing eco-friendly solutions that do not compromise product quality or performance, allowing consumers to access familiar products at competitive prices while minimizing environmental impact.
VeraMorph is a pharmaceutical company that is developing an oral dosage technology based on polymers. The company was founded in 2017 and is headquartered in Mansfield, Massachusetts.
MedApptic develops an electronic drug dispenser system. The company was founded in 2018 and is headquartered in Germantown, Maryland.
ACatechol, founded in 2016 and based in Pasadena, California, specializes in the development of biological-protein-based adhesives and biomimetic surface technologies. The company's innovative products are designed to prevent the spread of diseases by utilizing nanocomposite coatings and surface modifications applicable to various materials such as medical devices, implants, and textiles. These advanced coatings are effective in eliminating a wide range of bacteria and viruses, even in moist conditions. This capability enables the production of underwater glues, adhesives, coatings, and primers, offering a safer and more efficient alternative to traditional silane-based grafting methods, which can be slow, toxic, and inconsistent.
Solving gout using engineered probiotics
Proteios Technology, founded in 2015 and based in Issaquah, Washington, focuses on providing cost-effective solutions for scientists involved in biopharmaceutical development. The company has developed a flexible protein technology that supports the discovery and efficient manufacturing of advanced therapeutics. Its offerings include a fully automated, closed system designed for the isolation of target immune cells, which complies with Current Good Manufacturing Practice for cell therapy manufacturing. Additionally, Proteios Technology provides kits for the purification of recombinant proteins and antibodies, utilizing proprietary affinity tags and silica-based resins. This enables researchers to quickly and economically isolate proteins of interest, facilitating the progression from preclinical discovery to the end-to-end manufacturing of autologous cell therapies.
Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.
PhotoCide Protection develops self-disinfecting materials such fabrics, plastics, and coatings based on a disruptive technology that combines engineered cellulose (NFC) with photosensitizers (PS, compounds that react with room light and oxygen from the air) to emit an environmentally-friendly biocidal agent called ‘singlet’ oxygen that simultaneously destroys a wide range of harmful pathogens on surfaces.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
PhylloTech is focused on producing proteins and antibodies through a continuous plant expression system utilizing glandular secreting trichomes of Nicotiana tabacum. This innovative approach enables the production of difficult-to-manufacture proteins in a cost-effective manner. The system allows proteins to be secreted onto leaf surfaces, where they can be easily recovered with an extraction buffer, eliminating the need for time-consuming purification processes. This method not only reduces production costs but also facilitates rapid scalability, allowing for the cultivation of tens of thousands of plants. PhylloTech's environmentally-friendly system relies on basic inputs like light, water, and fertilizer, making it suitable for efficient growth in greenhouses or fields using existing agricultural practices. Additionally, the company aims to address plant disease challenges and enhance crop yields by employing enzymes to control bacterial pathogens, thereby reducing reliance on synthetic pesticides and microbial biocontrols.
Protabit engineers proteins for industrial, agricultural, and healthcare applications. Its platform technology is being developed via a strategic partnership with the Monsanto Company and the California Institute of Technology. Protabit’s protein engineering approach combines computational modeling with high-throughput screening and directed evolution to expand the diversity of protein sequences that can be explored to produce novel proteins.
Developer of diagnosis tool intended to build safe magnetic resonance imaging contrast agents. The company technology is iron-based contrast agents that can be used to produce high-quality magnetic resonance images of the brain, vasculature, liver, and kidneys, and for the detection of tumors resulting from cancer, providing medical professionals with a multipurpose agent that can be used to obtain high-quality images to treat patients effectively.
Interphase Materials Holdings, LLC, established in 2015 and headquartered in Pittsburgh, Pennsylvania, specializes in developing advanced materials and surface treatment technologies aimed at enhancing the efficiency of industrial cooling systems. The company's innovative solutions focus on improving heat transfer and reducing maintenance costs, catering to a diverse clientele that includes power plants, commercial and industrial HVAC systems, international heat exchanger manufacturers, and the U.S. Navy. Interphase's HTE system has demonstrated an improvement in heat exchanger heat transfer efficiency by 5-10% in preliminary tests, solidifying its role in advancing cooling technologies.
Manufacturer of industrial chemicals intended for replacement of precious metals. The company utilizes photocatalysts and light instead of heat to produce chemicals, offering features like low-energy consumption and the ability to upcycle captured carbon dioxide into valuable products, enabling the chemical industry to reduce its environmental footprint and potentially create new pathways for carbon capture and utilization.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
IDEM Systems provides drug testing kits and drug intelligence technology based on academic research. The testing system uses a novel chemical method to identify drugs, including heroin, other opiates, fentanyl and its derivatives, cocaine, and others. Among the devices are a handheld spectrometer, a sample pen, and a mobile application that allows users to access a proprietary database to identify suspect substances on-site accurately.
QCMedchain is an enterprise platform that enables pharma trade partners to digitize, verify, and secure shipments along the supply chain.
Nexilico, Inc. is an early-stage biotechnology company focused on advancing precision medicine through microbiome research and development. Founded in 2017 and based in Berkeley, California, Nexilico specializes in predictive and computational platforms that enhance drug design and development, as well as therapeutics clinical outcomes. The company aims to deepen scientific understanding of microbiomes and their impact on health and disease, utilizing this knowledge to create innovative microbiome-based technologies. By providing solutions that improve therapeutic efficacy, Nexilico positions itself as a key player in the evolving landscape of precision medicine.
Triangle Biotechnology is a biotechnology company dedicated to advancing research through innovative sample preparation solutions. The firm specializes in technologies that enhance biological sample workflows, particularly in the areas of DNA sharing for next-generation sequencing, chromatin shearing for chromatin immunoprecipitation (ChIP), and cell lysis. By utilizing efficient acoustic processing methods, Triangle Biotechnology aims to streamline the preparation of biological samples, thereby facilitating more effective research outcomes.
Capienda Biotech is a developer of an innovative biotechnology platform that streamlines the drug discovery process, significantly reducing both time and costs associated with developing new medicines. By addressing a critical bottleneck in the industry, Capienda's advanced bioanalytical system enhances the design of small molecules, allowing for higher quality drugs to enter clinical trials. Their high-throughput kinetics system offers twelve times the throughput compared to existing technologies, eliminating the need for specialist scientists to operate it. Capienda's product consists of a laboratory instrument system combined with assay chemicals, which also generates recurring revenues. This approach enables pharmacists to target medicine delivery more efficiently, ultimately accelerating the path to market for new therapeutics.
Developer of gastrointestinal therapeutic device designed for the alleviation of postoperative ileus and the restoration of gastrointestinal motility. The company's device aims to revolutionize medical science by using bioelectronic medicine for the treatment of diseases and injuries incurable pharmaceutically and is capable of developing miniaturized implantable device, while retaining sophisticated functionality with various electrode shape and number, enabling clinicians to treat diseases and injuries through neuromodulation.
VivoZ Biolabs is a biotechnology company focused on developing and commercializing innovative microfluidic technologies aimed at personalized medicine and drug discovery. The company's flagship product is a patented layered microfluidic tissue assay that closely mimics the dynamic three-dimensional tumor microenvironment. This platform allows for the maintenance of micro-tumor growth and functions ex vivo, facilitating mid-to-high throughput drug screening and diagnosis. By utilizing this technology, healthcare professionals can better predict and select candidate compounds during the drug discovery process, ultimately enhancing personalized cancer treatment options.